<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">BMC Med. Genet</journal-id>
<journal-title-group>
<journal-title>BMC Medical Genetics</journal-title>
</journal-title-group>
<issn pub-type="epub">1471-2350</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32423379</article-id>
<article-id pub-id-type="pmc">7236518</article-id>
<article-id pub-id-type="publisher-id">1028</article-id>
<article-id pub-id-type="doi">10.1186/s12881-020-01028-8</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>LARS2-</italic>Perrault syndrome: a new case report and literature review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Carminho-Rodrigues</surname>
<given-names>Maria Teresa</given-names>
</name>
<address>
<email>mcih@hcuge.ch</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Klee</surname>
<given-names>Phillipe</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Laurent</surname>
<given-names>Sacha</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guipponi</surname>
<given-names>Michel</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abramowicz</surname>
<given-names>Marc</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cao-van</surname>
<given-names>Hélène</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guinand</surname>
<given-names>Nils</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paoloni-Giacobino</surname>
<given-names>Ariane</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.150338.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0721 9812</institution-id><institution>Department of Genetic Medicine, </institution><institution>University Hospitals of Geneva Rue, </institution></institution-wrap>Gabrielle-Perret-Gentil 4, 1211 Genève 14, Switzerland </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.150338.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0721 9812</institution-id><institution>Departement of Pediatrics endocrinology, </institution><institution>Geneva University Hospital, </institution></institution-wrap>Geneva, Switzerland </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.150338.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0721 9812</institution-id><institution>Departement of ENT, </institution><institution>Geneva University Hospital, </institution></institution-wrap>Geneva, Switzerland </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>18</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>18</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>21</volume>
<elocation-id>109</elocation-id>
<history>
<date date-type="received">
<day>6</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>4</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2020</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">Perrault syndrome is a rare recessive and genetically heterogeneous disorder characterized by sensorineural hearing loss in males and females and gonadal dysgenesis in females. Mutations in seven different genes have been identified: <italic>HARS2, HSD17B4, CLLP, C10orf, ERAL1, TWNK</italic> and <italic>LARS2</italic>.</p>
<p id="Par2">To date, 19 variants have been reported in 18 individuals with <italic>LARS2</italic>-Perrault syndrome.</p>
</sec>
<sec>
<title>Case presentation</title>
<p id="Par3">Here we describe the case of an 8-year-old girl with compound heterozygous missense mutations in the <italic>LARS2</italic> gene. We identified two missense mutations [c.457A &gt; C, p.(Asn153His) and c.1565C &gt; A, p.(Thr522Asn)] and subsequent familial segregation showed that each parent had transmitted a mutation.</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par4">These results have implications for genetic counseling and provide insight into the functional role of <italic>LARS2</italic>. This case highlights the importance of an early diagnosis. Systematic genetic screening of children with hearing loss allows the early identification of a Perrault syndrome in order to ensure specific endocrinological surveillance and management to prevent secondary complications. Clinical data are compared with the other cases reported in the literature.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Perrault syndrome</kwd>
<kwd>LARS2</kwd>
<kwd>Whole-exome sequencing</kwd>
<kwd>Sensorineural hearing loss</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par8">Perrault syndrome (MIM: 233400) is a rare recessive genetically heterogeneous disorder characterized by sensorineural hearing loss in males and females and ovarian dysfunction in females [<xref ref-type="bibr" rid="CR1">1</xref>]. One-third of all patients have mutations in one of the seven known causative genes: <italic>HARS2</italic> (MIM 600783), <italic>HSD17B4</italic> (MIM 601860) <italic>CLPP</italic> (MIM 601119), <italic>C10orf2</italic>, (MIM606075), <italic>ERAL1</italic> (MIM 607435), <italic>TWNK</italic> (MIM 606075) and <italic>LARS2</italic> (MIM 604544) [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
<p id="Par9">More recently Tracewska-Siemiatkowska A et al., 2017 described a girl with a profound congenital hearing impairment and primary amenorrhea, like in Perrault Syndrome that also present additional features like progressive retinal degeneration, agenesis of the corpus callosum, and liver disease. A homozygous variant in <italic>YARS</italic> (MIM 603623), a gene previously related with Charcot-Marie-Tooth disease, was identified [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
<p id="Par10"><italic>LARS2</italic> encodes mitochondrial leucyl-tRNA synthetase (mtLeuRS), a 903 amino acid protein [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Aminoacyl-tRNA synthetases then attach specific amino acids to the 3′ ends of their cognate tRNAs, which is required in the cytoplasm and mitochondria for the translation of nuclear and mitochondrial encoded genes, respectively. Apart from two aminoacyl transfer RNA synthases, glycyl-tRNA synthetase and lysyl-tRNA synthetase, all other synthetases are encoded by separate genes for nuclear and mitochondrial functions [<xref ref-type="bibr" rid="CR6">6</xref>]. However, the human structure of mtLeuRS has not been elucidated.</p>
<p id="Par11">Apart from hearing loss and ovarian dysgenesis in females, some patients with Perrault syndrome may present neurological symptoms, such as learning disabilities, pyramidal signs, cerebellar ataxia and motor or sensory peripheral neuropathy [<xref ref-type="bibr" rid="CR7">7</xref>]. Here, we report the case of a young girl with bilateral severe hearing loss and bi-allellic mutations in <italic>LARS2</italic>.</p>
</sec>
<sec id="Sec2">
<title>Case presentation</title>
<p id="Par12">Our subject was an 8-year-old girl born at 36 weeks’ gestation and the first child of healthy non-consanguineous French parents. Family history was unremarkable. She has one healthy younger brother. Her birth weight was 2200 g. Newborn hearing screening was not performed at birth. Developmental milestones were normal with walking at the age of 16 months and first words at 12 months. At the age of 4 years, she started to present difficulties at nursery school that led to hearing screening. A bilateral severe sensorineural hearing loss was finally identified at the age of 7 years. Tonal audiograms (Fig. <xref ref-type="fig" rid="Fig1">1</xref>) did not show the upsloping pattern considered as typical for <italic>HARS2</italic> mutations and described in one case of a <italic>LARS2</italic> mutation [<xref ref-type="bibr" rid="CR8">8</xref>]. Hearing loss was severe on both sides with a discreet U-shaped curve centered on the 1000 Hz frequency. Transient otoacoustic emission and distortion product otoacoustic emission of both ears were absent. Auditory evoked potentials showed recognized curves at 80 dB on both sides and confirmed severe hearing loss. A temporal bone computed tomography scan and magnetic resonance imaging (MRI) performed to exclude other inner ear malformations were normal.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Tonal audiogram: on both sides</p></caption><graphic id="MO1" xlink:href="12881_2020_1028_Fig1_HTML"></graphic></fig></p>
<p id="Par13">At the age of 7 years, she received a cochlear implant on the right side (CI-522 cochlear) and responded well. One year later, the tonal free field audiogram showed 25 dB hearing levels on conversational frequencies and the vocal audiogram showed 100% of comprehension at 60 dB (intensity of normal voice). She had no neurological symptoms and her cognitive development was normal. At physical examination, she exhibited normal growth parameters and no dysmorphic features. She had astigmatism and three small café-au-lait macules. At the age of 8 years and 7 months, an endocrinological workup showed a chronological bone age that predicted a normal adult height. Hormonal assessments showed normal prepubertal values of follicle-stimulating hormone (FSH) (2.8 IU/L) and luteinizing hormone (LH) (0.7 U/L). Estradiol was below the detection limit of 17 pmol/l. Inhibin B was undetectable and the anti-Mullerian hormone (AMH) was 1.0 pmol/l. A pelvic ultrasound showed a normal prepubertal uterus measuring 32 mm in length. A right ovary measuring 16 × 6 × 6 × 6.5 mm was visualized. The left ovary was not clearly visualized. Thyroid function, insulin-like growth factor 1 and morning cortisol values (275 nmol/l) were normal. Glucose metabolism was normal with fasting blood glucose values of 4.7 mmol/l, insulin, 3.3 mIU/l, and glycated haemoglobin, 5.0% (31.0 mmol/mol).</p>
<sec id="Sec3">
<title>Molecular investigation</title>
<p id="Par14">Written informed consent from the parents was obtained prior to molecular studies and whole-exome sequencing was performed. Exome of the patient was captured using the SureSelet QXT Human All Exon V5 kit (Agilent Technologies Inc., Santa Clara, CA, USA) and sequenced on a NextSeq500 instrument (Illumina, San Diego, CA, USA).</p>
<p id="Par15">Reads mapping and variant calling were performed using BWA 0.7.13, Picard 2.9.0 and GATK HaplotypeCaller 3.7 and annotated with annovar 2017-07-17 and UCSC RefSeq (refGene) downloaded on 2018-08-10. The variants were searched for in various databases including dbSNP151, gnomAD 2.1, ClinVar 2018 and HGMD 2016.</p>
<p id="Par16">Pathogenicity prediction scores were obtained for missense variants using SIFT, PolyPhen, MutationTaster and CADD. Splicing effect alterations were assessed using dbscSNV.</p>
<p id="Par17">Our patient was found to carry two missense variants in the <italic>LARS2</italic> gene (NM_015340.3.3): c.457A &gt; C, p.(Asn153His) in exon 6 rs786205560, and c.1565C &gt; A, p.(Thr522Asn) in exon 14, rs199589947. Segregation analysis showed that the patient inherited the p.(Asn153His) variant from her father and p.(Thr522Asn) from her mother, consistent with an autosomal recessive mode of inheritance.</p>
<p id="Par18">The c.457A &gt; C, p.(Asn153His) variant is absent from the gnomAD database and has been classified once in ClinVar as “likely pathogenic” and once as “of uncertain clinical significance”. The amino acid change was predicted as pathogenic by all used algorithms. As the c.457A &gt; C variant changed the second nucleotide of exon 6, it could therefore have affected splicing, as predicted by the dbscSNV (score = 0.93) and recently reported in homozygosity by Al-Jaroudi et al. [<xref ref-type="bibr" rid="CR9">9</xref>] The c.1565C &gt; A, p.(Thr522Asn) variant is present in the gnomAD database (MAF = 2.8 × 10<sup>− 4</sup>) at a frequency compatible with a recessive mode of inheritance. It is also predicted as pathogenic by all used algorithms and is classified three times as “pathogenic” and once as “likely pathogenic” in ClinVar. It has already been reported in the literature as associated with Perrault syndrome [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. According to the ACMG guidelines [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>], we classified the p.(Asn153His) and p.(Thr522Asn) variants as pathogenic. The presence of these two variants in compound heterozygosity indicated that our patient presented a Perrault syndrome.</p>
</sec>
</sec>
<sec id="Sec4">
<title>Discussion and conclusions</title>
<p id="Par19">We described a young girl with a Perrault syndrome caused by a bi-allelic <italic>LARS2</italic> mutations. To our knowledge, our patient is only the second case of a p.Asn153His Perrault syndrome reported in the literature and the first case reported in compound heterozygosity. The first case reported with p.Asn153His in homozygosity was a 27- year-old female with Perrault syndrome type 1 [<xref ref-type="bibr" rid="CR9">9</xref>]. Regarding the second mutation, p.Thr522Asn, has been already described several times. It has also been implicated in a <italic>LARS2</italic> more severe phenotype described by Riley et al. [<xref ref-type="bibr" rid="CR13">13</xref>] They described a lethal, multisystem metabolic disorder characterized by severe lactic acidosis, hydrops and sideroblastic anemia, impaired cardiac function, disordered coagulation, pulmonary hypertension and progressive renal disease associated with the bi-allelic <italic>LARS2</italic> p.Thr522Asn and p.Ala430Val mutations [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Thus, the presence of p.Thr522Asn in our patient reinforced the idea that an association with the p.Ala430Val variant would have been more likely to be more damaging than p.Thr522Asn already described in homozygosity in Perrault syndrome [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p>
<p id="Par20">The identification of two missense variants both previously reported in patients with Perrault syndrome is in full agreement with all previous variants being of missense type, and it has been proposed that inactivating variants in these essential genes, may not be compatible with life.</p>
<p id="Par21">To date, 19 variants have been identified in <italic>LARS2</italic> in 18 individuals with Perrault syndrome (Table <xref ref-type="table" rid="Tab1">1</xref>). A comparison of the literature showed that bilateral hearing loss was highly variable, ranging from moderate to profound, and sometimes progressive. Of note, all individuals with a p.Thr522Asn Perrault syndrome, either homozygous or compound heterozygous, presented with sensorineural hearing loss, which was worse at low frequencies [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Age of onset also varied between 18 months and 32 years, but it was difficult to evaluate as detailed information was not always available.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>(adapted fom Kosaki et al. 2017): ID, identity of the patient; CI, cochlear implant; LF, low frequency; NA, not applicable; NR, not recorded: POI, primary ovarian insufeciency; SNHL, sensorineural hearing loss; FSH, follicular stimulating hormone; LH, luteininsing hormone.</p></caption><table frame="hsides" rules="groups"><thead><tr><th> ID</th><th>Family 1, II-1</th><th>Family 1, II-2</th><th>Family 1, II-3</th><th>Family 2, proband</th><th>II1</th><th>II3 proband</th><th>P2:II-1 proband</th><th>P2:II-2</th><th>P3:II-1 proband</th><th>P3:II-2</th><th>Patient III-3</th><th>III-1 proband</th><th>III-5</th><th>Patient 1 - proband</th><th>Patient 2</th><th>Patient 1</th><th>Patient 2</th><th>Patient 3</th><th>Patient 4</th><th>Index case</th><th>Our Patient</th></tr></thead><tbody><tr><td><bold>Variants</bold></td><td>c.1565C&gt;A (p.Thr522Asn)</td><td>c.1565C&gt;A (p.Thr522Asn)</td><td>c.1565C&gt;A (p.Thr522Asn)</td><td>c.1077delT (p.IIe360PhefsTer15) c.1886C&gt;T (p.Thr629Met)</td><td>c.899C&gt;T (p.Thr300Met) c.1912G&gt;A (p.Glu638Lys)</td><td>c.899C&gt;T (p.Thr300Met) c.1912G&gt;A (p.Glu638Lys)</td><td>c.1565C&gt;A (p.Thr522Asn)</td><td>c.1565C&gt;A (p.Thr522Asn)</td><td>c.351G&gt;C (p.Met117IIe) c.1565C&gt;A (p.Thr522Asn)</td><td>c.351G&gt;C (p.Met117IIe) c.1565C&gt;A (p.Thr522Asn)</td><td>c.1358G&gt;A (p.Arg453Gln) c.1886C&gt;T (p.Thr639Met)</td><td>c.1565C&gt;A (p.Thr522Asn)</td><td>c.1565C&gt;A (p.Thr522Asn)</td><td>c.880G&gt;A, p.(Glu294Lys); c.1556C&gt;T, p.(Thr519Met)</td><td>c.880G&gt;A, p.(Glu294Lys); c.1556C&gt;T, p.(Thr519Met)</td><td>c.462delT, p.(Lys155Asnfs*3); c.1120A&gt;C, p.(Ile374Leu)</td><td>c.1987C&gt;T, p.(Arg663Trp); c.371A&gt;T, p.(Asn124Ile)</td><td>c.516G&gt;T, p.(Arg172Ser); c.1028C&gt;T, p.(Thr343Met)</td><td>c.683G&gt;A, p.(Arg228His); c.880G&gt;A, p.(Glu294Lys)</td><td>c.457A&gt;C, p.(Asn153His)</td><td>c.457A&gt;C, p.(Asn153His); c.1565C&gt;A, p.(Thr522Asn)</td></tr><tr><td><bold>References</bold></td><td>Pierce et al. (2013) [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td>Pierce et al. (2013) [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td>Pierce et al. (2013) [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td>Pierce et al. (2013) [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td>Solda et al. (2016) [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td>Solda et al. (2016) [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td>Demain et al. (2017) [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td>Demain et al. (2017) [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td>Demain et al. (2017) [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td>Demain et al. (2017) [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td>Lerat et al. (2016) [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td>Zerkaoui et al. 2017 [<xref ref-type="bibr" rid="CR5">5</xref>]</td><td>Zerkaoui et al. 2017 [<xref ref-type="bibr" rid="CR5">5</xref>]</td><td>Kosaki et al. (2018) [<xref ref-type="bibr" rid="CR7">7</xref>]</td><td>Kosaki et al. (2018) [<xref ref-type="bibr" rid="CR7">7</xref>]</td><td>Van der Knaap et al. (2019) [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td>Van der Knaap et al. (2019) [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td>Van der Knaap et al. (2019) [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td>Van der Knaap et al. (2019) [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td>Al-Jaroudi et al. (2019) [<xref ref-type="bibr" rid="CR9">9</xref>]</td><td>our case</td></tr><tr><td><bold>Ethnicity</bold></td><td>Palestinian</td><td>Palestinian</td><td>Palestinian</td><td>Slovenian</td><td>Italian</td><td>Italian</td><td>Argentinian</td><td>Argentinian</td><td>White British</td><td>White British</td><td>Sri Lankan</td><td>Marrocan</td><td>Marrocan</td><td>NR</td><td>NR</td><td>NR</td><td>NR</td><td>NR</td><td>NR</td><td>Saudi arabia</td><td>France</td></tr><tr><td><bold>Consanguinity</bold></td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>Yes</td><td>Yes</td><td>No</td><td>No</td><td>NR</td><td>NR</td><td>NR</td><td>NR</td><td>Yes</td><td>No</td></tr><tr><td><bold>Sex</bold></td><td>Male</td><td>Female</td><td>Male</td><td>Female</td><td>Male</td><td>Female</td><td>Female</td><td>Male</td><td>Female</td><td>Male</td><td>Female</td><td>Female</td><td>Male</td><td>Female</td><td>Female</td><td>Female</td><td>Male</td><td>Male</td><td>Female</td><td>Female</td><td>Female</td></tr><tr><td><bold>Age at last assessment (years)</bold></td><td>17</td><td>17</td><td>13</td><td>30</td><td>40</td><td>31</td><td>27</td><td>26</td><td>25</td><td>26</td><td>NR</td><td>23</td><td>16</td><td>17</td><td>11</td><td>32</td><td>37</td><td>8</td><td>45</td><td>27</td><td>8</td></tr><tr><td><bold>Sensorineural hearing loss</bold></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><bold>Age at diagnosis (years)</bold></td><td>3-5</td><td>3-5</td><td>3-5</td><td>3-5</td><td>congenital</td><td>-</td><td>8</td><td>26</td><td>2.5</td><td>2.5</td><td>&lt;3</td><td>23</td><td>16</td><td>18 m.o.</td><td>congenital</td><td>congenital</td><td>congenital</td><td>congenital</td><td>congenital</td><td>congenital</td><td>4</td></tr><tr><td><bold>Degree of hearing loss</bold></td><td>Severe to profound</td><td>Right : severe at low frequencies, moderate at high frequencies. Left: moderate at low frequencies, mild at high frequencies</td><td>Severe to moderate at low frequencies, moderate to mild at high frequenies</td><td>Severe</td><td>Profound</td><td>Profound</td><td>Moderate</td><td>Mild/ moderate</td><td>Severe/ profound</td><td>Severe/ profound</td><td>Moderate</td><td>Moderate/ profound</td><td>Moderate/ profound</td><td>NR</td><td>NR</td><td>Profound</td><td>NR</td><td>Profound</td><td>NR</td><td>Profound</td><td>Severe</td></tr><tr><td><bold>Notes</bold></td><td>Bilateral LF SNHL</td><td>LF SNHL</td><td>Bilateral LF SNHL</td><td>None</td><td>Progressive SNHL</td><td>Progressive SNHL</td><td>LF</td><td>LF</td><td>LF</td><td>LF</td><td>Not progressive</td><td>Progressive</td><td>Progressive</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>Bilateral SNHL</td></tr><tr><td><bold>Intervention</bold></td><td>NR</td><td>No hearing aid</td><td>NR</td><td>NR</td><td>Bilatera CI</td><td>Bilatera CI</td><td>CI</td><td>NR</td><td>CI</td><td>NR</td><td>NR</td><td>Hearing aid</td><td>Hearing aid</td><td>NR</td><td>NR</td><td>NR</td><td>Hearing aid</td><td>Unilateral CI</td><td>Unilateral CI</td><td>NR</td><td>Unilateral CI</td></tr><tr><td><bold>Pelvic US</bold></td><td>NA</td><td>Small uterus, ovaries not visualized</td><td>NA</td><td>NR</td><td>NA</td><td>Bicornate uterus, hypoplastic left ovary, right ovary not visualised</td><td>Small uterus and ovaries</td><td>NA</td><td>Small uterus and ovaries</td><td>NA</td><td>NR</td><td>Small uterus, ovaries not visualized</td><td>NA</td><td>Hypotrophic uterus, ovaries not visualized</td><td>Hypotrophic uterus, ovaries not visualized</td><td></td><td>NA</td><td>NA</td><td>Streak ovaries</td><td>Hypoplastic uterus and streak ovaries</td><td>Left ovary not well visualised</td></tr><tr><td><bold>Menarche</bold></td><td>NA</td><td>No</td><td>NA</td><td>Yes</td><td>NA</td><td>Yes</td><td>No</td><td>NA</td><td>Yes</td><td>NA</td><td>No</td><td>NR</td><td>NA</td><td>No</td><td>No</td><td>Yes</td><td>NA</td><td>NA</td><td>Yes- 16</td><td>No</td><td>No</td></tr><tr><td><bold>POI- age if menarche achieved</bold></td><td>NA</td><td>Yes</td><td>NA</td><td>Yes-19</td><td>NA</td><td>Yes-28</td><td>NA</td><td>NA</td><td>Yes</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>Yes- 29</td><td>-</td><td>-</td><td>Yes- soon after menarche</td><td>-</td><td>NA</td></tr><tr><td><bold>FSH (IU/I)</bold></td><td>NR</td><td>76.9</td><td>NR</td><td>101</td><td>NR</td><td>118</td><td>99.6 (2.3-29)</td><td>NR</td><td>74 (&lt;30)</td><td>3.1 (1-11)</td><td>NR</td><td>51</td><td>NR</td><td>46.90 IU/L</td><td>22.06 IU/L</td><td>NR</td><td>NR</td><td>NR</td><td>NR</td><td>88.4 IU/L</td><td>NR</td></tr><tr><td><bold>LH (IU/I)</bold></td><td>NR</td><td>30.3</td><td>NR</td><td>NR</td><td>NR</td><td>45.4</td><td>48.0 (1.7-52)</td><td>NR</td><td>63 (&lt;30)</td><td>3.9 (1-11)</td><td>NR</td><td>16.29</td><td>NR</td><td>9.95 IU/L</td><td>3.04 IU/L</td><td>increased</td><td>NR</td><td>NR</td><td>increased</td><td>31.4 IU/L</td><td>NR</td></tr><tr><td><bold>Estradiol</bold></td><td>NA</td><td>NR</td><td>NA</td><td>NR</td><td>NA</td><td>NR</td><td>7.04 (10-388) pg/ml</td><td>NA</td><td>91 (&gt;180) pmol/l</td><td>NA</td><td>NR</td><td>NR</td><td>NA</td><td>&lt;10 pg/mL</td><td>&lt;10 pg/mL</td><td>decreased</td><td>NR</td><td>NR</td><td>decreased</td><td>213 pmol/ L</td><td>NR</td></tr><tr><td><bold>Neurological features</bold></td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>Developmental delay; behavioural problems; ataxic gait</td><td>Learning difficulties</td><td>Cerebellar ataxia; spasticity; swallowing difficulties</td><td>Hypotonia at birth; autistic behaviour; hyperactivity; aggression; atypical seizures; extrapyramidal dysfunction</td><td>Hypotonia at birth; hyperkinesia; self-mutilation; temper tantrums; aggression; mild pyramidal signs with brisk reflexes but no ataxia.</td><td>Pyramidal dysfunction; axial ataxia</td><td>No</td><td>No</td></tr><tr><td><bold>Additional features</bold></td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>Mild facial dysmorphia, hemidystrophy</td><td>Hypopadias, mild facial dysmorphia, normal testosterone</td><td>Cleft palate</td><td>Marfanoid habitus</td><td>Marfanoid habitus</td><td>Obesity; strabismus; osteoporosis; fatty liver; scoliosis</td><td></td><td></td><td>Macrocephaly; inguinal hernia; MRI showed early-onset vascular abnormalities</td><td></td><td>MRI showed early-onset vascular abnormalities</td><td>Marfanoid habitus; tarlov cysts; degenerative changes of the vertebral column</td><td>Astigmatism; 3 café-au-lait macules</td></tr></tbody></table></table-wrap></p>
<p id="Par22">Amenorrhea was most frequently primary and there appeared to be no obvious genotype-phenotype correlation [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
<p id="Par23">It is still not clear if <italic>LARS2</italic> can be responsible for an isolated hearing loss in the case of our young female patient and other prepubertal female patients described before. Follow up is essential to elucidate this question.</p>
<p id="Par24">Neurological symptoms were present in five families with neurodevelopmental delay, gait ataxia, behavioral problems and pyramidal dysfunction [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Van der Knaap et al. [<xref ref-type="bibr" rid="CR15">15</xref>] reported three patients who developed severe neurological features in later life. Cerebral MRIs performed at adult age showed extensive white matter abnormalities and additional signs of early-onset vascular abnormalities were observed in two patients [<xref ref-type="bibr" rid="CR13">13</xref>]. However, as most patients were relatively young at genetic diagnosis, it remains unclear whether neurological symptoms may develop later [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
<p id="Par25">In our patient, the fact that the diagnosis was made at an early age was crucial for this young girl. She was referred to the pediatric endocrinologist for evaluation and follow- up. Endocrinologic work-up showed normal prepubertal values for FSH, LH and estradiol. A pelvic ultrasound showed a normal prepubertal uterus and allowed visualization of a right gonad. Visualization of the left gonad was difficult. Inhibin B and AMH were measured at a time point where both hormones are naturally low: inhibin B was undetectable and AMH was below normal values. While visualization of the gonads is reassuring, a follow-up is necessary to determine the ovarian function of the patient. Thyroid function and glucose metabolism were analyzed in the context of previous reports of abnormalities of these parameters [<xref ref-type="bibr" rid="CR16">16</xref>] and proved normal.</p>
<p id="Par26">Pubertal development will be monitored in the future in order to induce puberty and permit normal bone mineralization. Should ovarian insufficiency be confirmed, oocyte cryopreservation should be considered. Hearing loss should be assessed and treated by a multidisciplinary team including an audiologist and otolaryngologist. Possible interventions for those with hearing loss include special educational resources, hearing aids, vibrotactile devices and cochlear implantation, which is an option for children older than 12 months with severe-to-profound hearing loss [<xref ref-type="bibr" rid="CR17">17</xref>]. In addition, due to highly intra- and inter-clinical variably, we tested her younger brother to exclude the presence of familial mutations and hence, the risk of hearing loss.</p>
<p id="Par27">More recently, leukodystrophy was also associated with <italic>LARS2</italic> pathogenic variants [<xref ref-type="bibr" rid="CR15">15</xref>]. Concerning the development of neurological problems, systematic neurological surveillance is still not indicated, but it should be kept in mind that these may eventually develop later in life. More reports of older patients will help to elucidate the eventual progression of this syndrome.</p>
<p id="Par28">Our case demonstrates that whole-exome sequencing is essential in the diagnosis of hearing loss in children. Benefits of receiving an early genetic diagnosis include the provision of prognostic information, streamlined care, accurate recurrence risk advice and, where appropriate, screening and treatment for associated health conditions.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>FSH</term>
<def>
<p id="Par5">Follicle stimulating hormone</p>
</def>
</def-item>
<def-item>
<term>LH</term>
<def>
<p id="Par6">Luteinizing hormone</p>
</def>
</def-item>
<def-item>
<term>AMH</term>
<def>
<p id="Par7">Anti-Müllerian Hormone</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Publisher’s Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>MC examined the patient and the genetic data and was a major contributor in writing the manuscript. PK follows the patient in the endocrinology clinic and was a major contributor in writing the manuscript. SL performed and analyzed the genetic analysis and was a major contributor in writing the manuscript. MG performed and analyzed the genetic analysis and was a major contributor in writing the manuscript. MA was a major contributor in revising the manuscript. HCV follows the patient in ORL clinics and was a major contributor in writing the manuscript. NG follows the patient in ORL clinics and was a major contributor in writing the manuscript. AG examined the patient and the genetic data and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>No funding.</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>All data generated or analyzed during this study are included in this published article. The mutations described in the current study are available in the ClinVar repository [ID: 55871 and 191173] <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/variation/191173/">https://www.ncbi.nlm.nih.gov/clinvar/variation/191173/</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/variation/55871/">https://www.ncbi.nlm.nih.gov/clinvar/variation/55871/</ext-link> . The complete sequence datasets generated during the current study are not publicly available because individual privacy could be compromised.</p>
</notes>
<notes id="FPar1">
<title>Ethics approval and consent to participate</title>
<p id="Par29">Written informed consent was obtained from patient’s parents.</p>
</notes>
<notes id="FPar2">
<title>Consent for publication</title>
<p id="Par30">Written informed consent was obtained from patient’s parents.</p>
</notes>
<notes id="FPar3" notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par31">The authors declare that they have no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pallister</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Opitz</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>The Perrault syndrome: autosomal recessive ovarian dysgenesis with facultative, non-sex-limited sensorineural deafness</article-title>
<source/>Am J Med Genet
          <year>1979</year>
<volume>4</volume>
<issue>3</issue>
<fpage>239</fpage>
<lpage>246</lpage>
<pub-id pub-id-type="pmid">517579</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brodie</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Saiyed</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Truscott</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Dougan</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Perrault syndrome type 3 caused by diverse molecular defects in CLPP</article-title>
<source/>Sci Rep
          <year>2018</year>
<volume>8</volume>
<issue>1</issue>
<fpage>12862</fpage>
<pub-id pub-id-type="pmid">30150665</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tracewska-Siemiątkowska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Haer-Wigman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bosch</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An expanded multi-organ disease phenotype associated with mutations in YARS</article-title>
<source/>Genes (Basel)
          <year>2017</year>
<volume>8</volume>
<issue>12</issue>
<fpage>381</fpage>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bullard</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Spremulli</surname>
<given-names>LL</given-names>
</name>
</person-group>
<article-title>Expression and characterization of the human mitochondrial leucyl-tRNA synthetase</article-title>
<source/>Biochim Biophys Acta
          <year>2000</year>
<volume>1490</volume>
<issue>3</issue>
<fpage>245</fpage>
<lpage>258</lpage>
<pub-id pub-id-type="pmid">10684970</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zerkaoui</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Demain</surname>
<given-names>LAM</given-names>
</name>
<name>
<surname>Cherkaoui Jaouad</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ratbi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Amjoud</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Urquhart</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>O'Sullivan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Sefiani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Marfanoid habitus is a nonspecific feature of Perrault syndrome</article-title>
<source/>Clin Dysmorphol
          <year>2017</year>
<volume>26</volume>
<issue>4</issue>
<fpage>200</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="pmid">28832386</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diodato</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ghezzi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tiranti</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>The mitochondrial aminoacyl tRNA synthetases: genes and syndromes</article-title>
<source/>Int J of Cell Biol
          <year>2014</year>
<volume>2014</volume>
<fpage>787956</fpage>
<pub-id pub-id-type="pmid">24639874</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosaki</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Horikawa</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fujii</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kosaki</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Biallelic mutations in LARS2 can cause Perrault syndrome type 2 with neurologic symptoms</article-title>
<source/>Am J Med Genet Part A
          <year>2018</year>
<volume>176</volume>
<issue>2</issue>
<fpage>404</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="pmid">29205794</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pierce</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Gersak</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Michaelson-Cohen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Malach</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Klevit</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>King</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Levy-Lahad</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Mutations in LARS2, encoding mitochondrial leucyl-tRNA synthetase, lead to premature ovarian failure and hearing loss in Perrault syndrome</article-title>
<source/>Am J Hum Genet
          <year>2013</year>
<volume>92</volume>
<issue>4</issue>
<fpage>614</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="pmid">23541342</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Jaroudi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Enabi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>AlThagafi</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Perrault syndrome with amenorrhea, infertility, Tarlov cyst, and degenerative disc</article-title>
<source/>Gynecol Endocrinol
          <year>2019</year>
<volume>35</volume>
<issue>12</issue>
<fpage>1037</fpage>
<lpage>1039</lpage>
<pub-id pub-id-type="pmid">31274036</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demain</surname>
<given-names>LAM</given-names>
</name>
<name>
<surname>Urquhart</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>O’Sullivan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Bhaskar</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Jenkinson</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Lourenco</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Heiberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Shalev</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Mackinnon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Munro</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Newbury-Ecob</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>O'Keefe</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>WG</given-names>
</name>
</person-group>
<article-title>Expanding the genotypic spectrum of Perrault syndrome</article-title>
<source/>Clin Genet
          <year>2017</year>
<volume>91</volume>
<issue>2</issue>
<fpage>302</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="pmid">26970254</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines</article-title>
<source/>Am J Hum Genet
          <year>2017</year>
<volume>100</volume>
<issue>2</issue>
<fpage>267</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="pmid">28132688</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richards</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aziz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bale</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bick</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gastier-Foster</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grody</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Hegde</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lyon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Spector</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Voelkerding</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rehm</surname>
<given-names>HL</given-names>
</name>
</person-group>
<article-title>ACMG laboratory quality assurance committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the association for molecular pathology</article-title>
<source/>Genet Med
          <year>2015</year>
<volume>17</volume>
<issue>5</issue>
<fpage>405</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="pmid">25741868</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riley</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Rudinger-Thirion</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schmitz-Abe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Thorburn</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Teo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Arbuckle</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Campagna</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Frugier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Markianos</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sue</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Fleming</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Christodoulou</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>LARS2 variants associated with Hydrops, lactic acidosis, Sideroblastic Anemia, and multisystem failure</article-title>
<source/>JIMD Rep
          <year>2016</year>
<volume>28</volume>
<fpage>49</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="pmid">26537577</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soldà</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Caccia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Robusto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chiereghin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Castorina</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ambrosetti</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Duga</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Asselta</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>First Independent Replication of the Involvement of LARS2 in Perrault Syndrome by Whole-Exome Sequencing of an Italian Family</article-title>
<source/>J Hum Genet
          <year>2016</year>
<volume>61</volume>
<issue>4</issue>
<fpage>295</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="pmid">26657938</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Der Knaap</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Bugiani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mendes</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Riley</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>DEC</given-names>
</name>
<name>
<surname>Rudinger-Thirion</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Frugier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Breur</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Gaalen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schouten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Willems</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Waisfisz</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Mau-Them</surname>
<given-names>FT</given-names>
</name>
<name>
<surname>Rodenburg</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Taft</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Keren</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Christodoulou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Depienne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Simons</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Salomons</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Mochel</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Biallelic variants in LARS2 and KARS cause deafness and (ovario)leukodystrophy</article-title>
<source/>Neurology.
          <year>2019</year>
<volume>92</volume>
<issue>11</issue>
<fpage>e1225</fpage>
<lpage>e1237</lpage>
<pub-id pub-id-type="pmid">30737337</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lerat</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jonard</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Loundon</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Christin-Maitre</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lacombe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Goizet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rouzier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Van Maldergem</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gherbi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Garabedian</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Bonnefont</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Touraine</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mosnier</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Munnich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Denoyelle</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Marlin</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>An application of NGS for molecular investigations in Perrault Syndrome: study of 14 families and review of the literature</article-title>
<source/>Hum Mutat
          <year>2016</year>
<volume>37</volume>
<fpage>1354</fpage>
<lpage>1362</lpage>
<pub-id pub-id-type="pmid">27650058</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<mixed-citation publication-type="other">Newman WG, Friedman TB, Conway GS, Demain LAM. Perrault Syndrome. 1993; In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. Seattle (WA): University of Washington, Seattle; 1993-2020.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>